September 10, 2014 - ZOLL Lifevest Wearable Defibrillator to be Showcased at Heart Failure Society of America 2014
| MEDIA CONTACT: |
Diane Egan |
ZOLL LIFEVEST WEARABLE DEFIBRILLATOR TO BE SHOWCASED AT HEART FAILURE SOCIETY OF AMERICA
SEPTEMBER 10, 2014—CHELMSFORD, MASS.—ZOLL Medical Corporation, a manufacturer of medical devices and related software solutions, announced today that that it will display the LifeVest® Wearable Defibrillator in Booth #300 at the 2014 Heart Failure Society of America (HFSA) Annual Meeting, September 14-17 in Las Vegas.
The LifeVest will be discussed during a scientific presentation:
Chingping Wan, MD, ZOLL, will present “Bridging to Recovery: Experience with the Wearable Cardioverter Defibrillator in Patients with Tachycardia-induced Cardiomyopathy," Monday, September 15, 5:15 p.m., Abstract #465, VADs/Transplant/Surgery Category, Exhibit Hall.
Each year, more than 650,000 new cases of heart failure (HF) are diagnosed in the United States.1 Patients newly diagnosed with HF have a high mortality rate, up to 40% in the first year, including a high risk of sudden cardiac death (SCD).2 Compared to the general population, SCD occurs 6-9 times more frequently in HF patients,3 and an acute event such as hospitalization for heart failure decompensation or myocardial infarction increases the SCD risk.4,5 Likewise, an HF patient’s condition can improve from the benefits of optimized medical therapy, which can require up to 3 months or more to stabilize.6
The LifeVest is worn by patients at risk for SCD, including patients with cardiomyopathy or congestive heart failure that places them at particular risk. The LifeVest provides protection during their changing condition and while permanent SCD risk has not been established, allowing a patient’s physician time to assess his or her long-term arrhythmic risk and make appropriate plans.
The LifeVest is lightweight and easy to wear, allowing patients to return to their activities of daily living, while having the peace of mind that they are protected from SCD. The LifeVest continuously monitors the patient’s heart and, if a life-threatening heart rhythm is detected, the device delivers a treatment shock to restore normal heart rhythm.
The LifeVest is used for a wide range of patient conditions or situations, including following a heart attack, and before or after bypass surgery or stent placement, as well as cardiomyopathy or congestive heart failure that places patients at particular risk.
The LifeVest is covered by most health plans in the United States, including commercial, state, and federal plans.
About ZOLL Medical Corporation
ZOLL Medical Corporation, an Asahi Kasei Group company, develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies that help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and acute critical care. For more information, visit www.zoll.com.
About Asahi Kasei
The Asahi Kasei Group is a diversified group of companies led by holding company Asahi Kasei Corp., with operations in the chemicals and fibers, homes and construction materials, electronics, and health care business sectors. Its health care operations include devices and systems for acute critical care, dialysis, therapeutic apheresis, transfusion, and manufacture of biotherapeutics, as well as pharmaceuticals, diagnostic reagents, and nutritional products. With more than 29,000 employees around the world, the Asahi Kasei Group serves customers in more than 100 countries. For more information, visit www.asahi-kasei.co.jp/asahi/en/.
Copyright © 2014 ZOLL Medical Corporation. All rights reserved. IVTM, LifeBridge, LifeVest, Thermogard XP, and ZOLL are trademarks or registered trademarks of ZOLL Medical Corporation in the United States and/or other countries. Asahi Kasei is a registered trademark of Asahi Kasei Corporation. All trademarks are the property of their respective owners.
1Yancy C, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. JACC. 2013;62(16):e147-e239.
2O’Connor C, et al. Predictors of Mortality after Discharge in Patients Hospitalized with Heart Failure: An Analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Amer Heart J. 2008;156:662-73.
3Rosamond W, et al., Heart Disease and Stroke Statistics32008 Update: A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2008;117: e25-46.
4Adabag AS, Therneau TM, Gersh BJ, et al. Sudden Death after Myocardial Infarction. JAMA. 2008;300:2022-2029.
5Solomon SD, Zelenkofske S, McMurray JV, et al. Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both. NEJM. 2005;352:2581-2588.
6Hall SA, et al. Time Course of Improvement in Left Ventricular Function, Mass and Geometry in Patients with Congestive Heart Failure Treated with Beta-adrenergic Blockade. JACC. 1995;25:1154-61.